U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758231) titled 'Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics' on Aug. 05.
Brief Summary: This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
GLP-1
Alcohol
Intervention:
DRUG: Acute Ethanol Dose
Time 0, participants will self-administer an oral ethanol beverage (vodka and sugar-free cherry Kool aid) calculated to reach a peak Breath Alcohol Concentration (BrAC) of 0.08 g/dL using the Wid...